ClinicalTrials.gg

Program

sapablursen

Also written as “Sapablursen” and “IONIS TMPRSS6-Lrx”.

Its studies are mostly in Polycythemia Vera · beta-Thalassemia · Thalassemia, led by 2 companies.

Furthest: phase 3, since Aug 14, 20194 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticals30 open or runningphase 2since Aug 14, 2019May 18, 2017none ahead
Ono Pharmaceutical11 open or runningphase 3since Feb 18, 2026Feb 18, 2026Sep 2028phase 3 · NCT07429266

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2017First study: phase 1 study in ThalassemiaNew to Ionis PharmaceuticalsIonis Pharmaceuticals · NCT03165864 · 36 enrolled · Australia
  2. Aug 14, 2019Phase 2 study in beta-ThalassemiaIonis Pharmaceuticals · NCT04059406 · 29 enrolled · Australia, Greece, Lebanon and more
  3. Nov 20, 2021Phase 2 study in Polycythemia VeraIonis Pharmaceuticals · NCT05143957 · 50 enrolled · United States, Australia, Canada and more
  4. Feb 18, 2026Ono Pharmaceutical's first study: phase 3 study in Polycythemia VeraNew to Ono PharmaceuticalOno Pharmaceutical · NCT07429266 · 250 planned · United States, Australia, Austria and more

Ahead

  1. Sep 2028Primary completion: phase 3 study in Polycythemia VeraOno Pharmaceutical · NCT07429266

TargetBeta

TMPRSS6 →read by rule
“An antisense oligonucleotide (ASO) targeting the transmembrane protease serine 6 (TMPRSS6) mRNA and ”NCIt, by rule

Other programs on TMPRSS6

ProgramCompanyFurthest phaseStudies
AG-236ruleAgios Pharmaceuticalsphase 32
Anti-TMPRSS6 Monoclonal Antibody DISC-3405ruledisc-medicine-incphase 26

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07429266Polycythemia Vera · United States, Australia, Austria and more3RecruitingOno PharmaceuticalSep 2028250
NCT05143957Polycythemia Vera · United States, Australia, Canada and more2CompletedIonis PharmaceuticalsJun 26, 202550
NCT04059406beta-Thalassemia · Australia, Greece, Lebanon and more2TerminatedIonis PharmaceuticalsMar 28, 202329
NCT03165864Thalassemia · Australia1CompletedIonis PharmaceuticalsSep 25, 201836

How it is read

Names in the registry

  • “sapablursen”, 2 entries
  • “Sapablursen”, 1 entry
  • “IONIS TMPRSS6-Lrx”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.